Retinal and Choriocapillaris Vascular Changes in Patients Affected by Different Clinical Phenotypes of β-Thalassemia: An Optical Coherence Tomography Angiography Study

Gilda Cennamo 1*, Daniela Montorio 2*, Giuliano Mazzella 2, Paolo Ricchi 3, Silvia Costantini 3, Anna Spasiano 3, Aldo Filosa 3, Maria Rosaria Storino 4, Francesca Aquila 5, Fausto Tranfa 2,* and Michela Grosso 4,5*

Citation: Cennamo, G.; Montorio, D.; Mazzella, G.; Ricchi, P.; Costantini, S.; Spasiano, A.; Filosa, A.; Storino, M.R.; Aquila, F.; Tranfa, F.; et al. Retinal and Choriocapillaris Vascular Changes in Patients Affected by Different Clinical Phenotypes of β-Thalassemia: An Optical Coherence Tomography Angiography Study. Biology 2021, 10, 276. https://doi.org/10.3390/biology10040276

Abstract: In this cross-sectional study we assessed the vascular alterations in retinal and choriocapillaris perfusion in patients affected by β-thalassemia, by means of optical coherence tomography angiography (OCTA). A total of 124 eyes of 62 patients (mean age 44.74 ± 5.79 years old) affected by β-thalassemia (transfusion dependent thalassemia (TDT), non-transfusion dependent thalassemia (NTDT) and minor) were compared to 40 eyes of twenty healthy subjects. We evaluated the vessel density (VD) in superficial capillary plexus, deep capillary plexus, radial peripapillary capillary, choriocapillaris and the foveal avascular zone area. The TDT group showed a statistically significant reduction in retinal and choriocapillaris VD respect to controls and the other groups (p < 0.05). No statistically significant difference was found in OCTA parameters between β-thalassemia minor and controls. The NTDT group showed a significant reduction in VD in deep capillary plexus respect to controls and β-thalassemia minor. Significant negative correlations were shown in TDT group between foveal avascular zone and hemoglobin \( r = -0.437, p = 0.044 \) and between ferritin levels and VD of choriocapillaris \( r = -0.431, p = 0.038 \). The OCTA parameters provided a deeper understanding on retinal and choriocapillaris vascular impairment affected by tissue hypoxia levels and the oxidative stress in different clinical phenotypes of the β-thalassemia.

Keywords: transfusion dependent thalassemia; non transfusion dependent thalassemia; thalassemia minor; optical coherence tomography angiography; vessel density; spectral domain optical coherence tomography
1. Introduction

Beta-thalassemia (β-thalassemia) is one of the most common genetic hemoglobinopathies characterized by a defective β globulin chain synthesis leading to hemolysis and ineffective erythropoiesis [1–3].

The patients with transfusion dependent thalassemia (TDT) need regular lifelong blood transfusion leading to iron overload in the tissues that requires an iron chelation therapy [4–7].

Several studies reported that both iron accumulation and iron-chelating agents determined ocular manifestations, such as retinal pigment epithelial (RPE) degeneration, RPE mottling, cataract, optic neuropathy, retinal venous tortuosity [8–11]. Moreover, the angioid streaks were reported in β-thalassemia patients hypothesizing different pathogenetic mechanisms, such as vascular obstruction affecting the choriocapillary circulation or chronic hemolysis leading to iron deposition [12].

The other forms of β-thalassemia present different clinical phenotypes. β-thalassemia minor, characterized by a presence of only a gene mutation, appears with a mild anemia not requiring blood transfusions [13] such as non-transfusion dependent thalassemia (NTDT), characterized by a different genetic compound that presents a clinical phenotype between β-thalassemia minor and TDT. It causes mild to severe hemolytic anemia and only in specific situations, such as pregnancy, surgery or serious intercurrent infection requiring a few blood transfusions [14].

β-thalassemia is a hematological disorder that determines a tissue hypoxia status and oxidative damages [15,16] that may influence the retinal and choroidal circulation.

The use of optical coherence tomography angiography (OCTA), advanced and non-invasive imaging technique, provided a quantitative evaluation of retinal and choriocapillaris vascular networks, leading to a deeper understanding of their pathological alterations in several ocular diseases [17,18].

The aim of this cross-sectional study was to investigate the retinal and choriocapillaris vascular changes in patients with different forms of β-thalassemia.

2. Materials and Methods

2.1. Subjects

A total of one hundred and twenty-four eyes of 62 patients affected by β-thalassemia were enrolled in this cross-sectional study from October 2019 to February 2020 at the Eye Clinic of the University “Federico II”, Naples in collaboration with Rare Red Blood Disease Unit of Cardarelli Hospital in Naples, Italy.

The patients were classified into 3 groups: TDT, NTDT and β thalassemia minor.

A detailed analysis of the clinical and hematological parameters was performed in all participants. Hemoglobin (g/dL) and serum ferritin (ng/mL) levels, the type and duration of chelating therapy were investigated.

All patients underwent blood transfusions approximately twice a month, and deferriprone (DFP), deferasirox (DFX) and desferal (DFO) were used as chelating agents.

Forty eyes of twenty healthy subjects without any history of intraocular surgery, vitreoretinal diseases and abnormal ophtalmic examination were included in the control group.

In order to obtain a complete ophtalmological examination, all subjects underwent the evaluation of best-corrected visual acuity (BCVA), slit-lamp biomicroscopy assessment, intraocular pressure measurement, fundus examination, spectral domain (SD)-OCT and OCTA.

Exclusion criteria included previous intraocular surgery, congenital eye disease, myopia greater than 6 diopters, history of glaucoma, retinal vascular diseases, significant lens opacities to avoid low-quality OCT and OCTA images.

The study adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from the patients enrolled in the study. The research protocol was registered on ClinicalTrials.gov (NCT04582110).
2.2. Spectral Domain Optical Coherence Tomography

SD-OCT (software RTVue XR version 2017.1.0.151, Optovue Inc., Fremont, CA, USA) was used to examine the retinal nerve fiber layer (RNFL) and ganglion cell complex thickness in all patients. The optic nerve head (ONH) analysis measured the retinal nerve fiber layer thickness, calculated along a 3.45-mm diameter circle around the optic disc. The ganglion cell complex thickness was measured from the internal limiting membrane to the outer boundary of the inner plexiform layer in a 7 × 7 mm grid of the macula centered 1-mm temporal to the fovea [19]. OCTA images with a signal strength index (SSI) less than 40, and residual motion artifacts were excluded from the analysis.

2.3. Optical Coherence Tomography Angiography

All the subjects underwent OCTA (Optovue Angiovue System, software ReVue XR version 2017.1.0.151, Optovue Inc., Fremont, CA, USA).

Macular capillary network was evaluated in scans centered on the fovea by performing a 6 mm × 6 mm area divided, according to the ETDRS classification of diabetic retinopathy, in whole image, fovea and parafovea.

The AngioAnalytic™ software automatically analyzed the vessel density (VD) in two different retinal vascular networks: superficial capillary plexus, deep capillary plexus and in the choriocapillaris, as previously described [20,21]. The VD was defined as the percentage area occupied by the microvasculature in the whole scan area and in all sections [21].

The VD of the radial peripapillary capillary plexus, analyzing the whole papillary region, inside the disc and peripapillary region with an area scan of 4.5 × 4.5 mm, was automatically calculated by the Angio Vue disc mode [22].

Angio Vue software automatically calculated the foveal avascular zone area in square millimeters over the 6 mm × 6 mm macular area in the full retinal plexus [23].

The 3D Projection Artifact Removal (PAR) algorithm, included in the software, improved the quality of OCTA images.

OCTA images with an SSI less than 60 and residual motion artifacts were excluded from the analysis.

2.4. Statistical Analysis

The Statistical Package for Social Sciences (Version 25 for Windows; SPSS Inc, Chicago, IL, USA) was used for statistical analysis. The differences in OCTA and SD-OCT parameters among controls and the three patients study groups were evaluated by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc analysis. Pearson’s correlation was used to examine the relationships among the hematological variables and structural SD-OCT, OCTA parameters in each β-thalassemia group. A p value of <0.05 was considered statistically significant.

3. Results

A total of one hundred and twenty-four eyes of 62 patients (male 26, female 36; mean age 44.74 ± 5.79 years old) with β-thalassemia were recruited in this cross-sectional study.

The patients and controls were not significantly different in terms of age (p = 0.855) and sex (p = 0.158). BCVA was not significantly different between the controls and the three study groups (p = 0.765) (Table 1). The hemoglobin and ferritin levels turned to be statistically increased in TDT group with respect to the other two β-thalassemia study groups (p < 0.001).

A statistically significant reduction in ganglion cell complex parameters was found in the TDT group with respect to other groups, likewise also the retinal nerve fiber layer parameters turned out to be significantly reduced with respect to controls and the study groups. No statistically significant difference was found in structural SD-OCT parameters (ganglion cell complex, retinal nerve fiber layer) between β-thalassemia minor and NTDT group with respect to controls (p > 0.05) (Table 2, Figure 1).
Table 1. Demographic, ophthalmologic and hematologic characteristics of controls and β-thalassemia patients.

|                      | Control Group | TDT  | NTDT | β-Thalassemia Minor | p Value |
|----------------------|---------------|------|------|---------------------|---------|
| **Age (years)**      | 44 ± 5.3      | 45.2 ± 3.6 | 43.88 ± 5.4 | 44.91 ± 7.5 | 0.855 |
| **Gender (male/female)** | 8/12         | 8/13 | 4/13 | 14/10              | 0.158‡ |
| BCVA (logMAR)        | 0.05 ± 0.08   | 0.06 ± 0.06 | 0.05 ± 0.06 | 0.03 ± 0.05 | 0.765 |
| Hemoglobin (g/dL)    | 12.02 ± 0.90  | 10 ± 0.42  | 9.67 ± 0.86  | 11.58 ± 1.39 | <0.001|
| Ferritin (nmol/L)    | 72.85 ± 26.36 | 1459.05 ± 1745.27 | 485.35 ± 416.89 | 161.52 ± 192.92 | <0.001|

Data are expressed as mean ± SD, TDT: Transfusion Dependent Thalassemia, NTDT: Non-Transfusion Dependent Thalassemia, BCVA: Best Corrected Visual Acuity; logMAR: logarithm of the minimum angle of resolution. One-way analysis of variance (ANOVA) followed by Bonferroni post hoc analysis. ‡ Chi-squared test Statistical significance p value < 0.05.

Table 2. Differences in SD-OCT parameters among the controls and β-thalassemia patients.

|                      | Control Group | TDT  | NTDT | p Value * | β-Thalassemia Minor | p Value † | Anova |
|----------------------|---------------|------|------|-----------|--------------------|-----------|-------|
| GCC (µm) Average     | 103.07 ± 7.69 | 97.50 ± 9.23 | 0.011 | 101.35 ± 5.98 | 0.465 | 102.37 ± 8.30 | 0.851 | 0.008 |
| Superior             | 105.87 ± 7.61 | 98.73 ± 8.74 | 0.001 | 104.17 ± 7.50 | 0.758 | 105.10 ± 9.76 | 0.994 | 0.001 |
| Inferior             | 104.47 ± 7.87 | 96.59 ± 7.50 | <0.001 | 100.02 ± 5.82 | 0.053 | 103.33 ± 7.15 | 0.742 | <0.001|
| RNFL (µm) Average    | 110.80 ± 7.58 | 99.73 ± 8.48 | <0.001 | 113.05 ± 7.24 | 0.819 | 110.25 ± 6.03 | 1    | <0.001|
| Superior             | 112.85 ± 6.72 | 101.04 ± 7.47 | <0.001 | 114.20 ± 6.79 | 0.784 | 111.20 ± 6.20 | 0.865 | <0.001|
| Inferior             | 108.30 ± 7.75 | 98.47 ± 7.70 | <0.001 | 109.29 ± 7.68 | 0.811 | 106.62 ± 6.82 | 0.892 | <0.001|

Data are expressed as mean ± SD, TDT: Transfusion Dependent Thalassemia, NTDT: Non-Transfusion Dependent Thalassemia, GCC: Ganglion Cell Complex, RNFL: Retinal Nerve Fiber Layer. p: TDT vs. control group, p *: NTDT vs. control group, p †: β-thalassemia minor vs. control group, One-way analysis of variance (ANOVA) followed by Bonferroni post hoc analysis, Statistical significance p value < 0.05.

At OCTA examination, the TDT group showed a statistically significant reduction in VD of the SCP respect to controls and the other study groups in each macular sector (p < 0.001). The same behavior was found for VD of the deep capillary plexus, choriocapillaris, foveal avascular zone and radial peripapillary capillary plexus in the comparison between TDT and the other groups (p < 0.05).

The NTDT group revealed no statistically significant differences in OCTA parameters, except for VD of the deep capillary plexus that turned to be out lower respect to controls and the other study groups in each macular sector (p < 0.001). The same behavior was found for VD of the SCP respect to controls and the other study groups in each macular sector (p < 0.001). The NTDT group revealed no statistically significant differences in OCTA parameters, except for VD of the deep capillary plexus that turned to be out lower respect to controls and the other study groups in each macular sector (p < 0.001).

Additionally, the β-thalassemia minor showed similar values in the VD of retinal and choriocapillaris with respect to controls (p > 0.05) (Table 3, Figure 2).

Table 3. Differences in OCT angiography parameters among the controls and β-thalassemia patients.

|                      | Control Group | TDT  | NTDT | p Value * | β-Thalassemia Minor | p Value † | Anova |
|----------------------|---------------|------|------|-----------|--------------------|-----------|-------|
| SCP (%)              | 50.72 ± 3.39  | 46.78 ± 4.37 | <0.001 | 50.78 ± 3.51 | 1 | 52.10 ± 4.12 | 0.603 | <0.001|
| Parafovea            | 52.56 ± 6.37  | 48.22 ± 6.42 | 0.006 | 53.87 ± 3.97 | 0.936 | 54.30 ± 5.66 | 0.999 | <0.001|
| Fovea                | 23.55 ± 5.33  | 18.60 ± 4.03 | <0.001 | 22.77 ± 5.25 | 0.945 | 21.20 ± 6.81 | 0.291 | <0.001|
| DCP (%)              | 55.74 ± 6.31  | 50.40 ± 7.47 | 0.007 | 50.96 ± 7.53 | 0.034 | 55.76 ± 7.79 | 1    | <0.001|
| Whole image          | 58.07 ± 7.18  | 53.47 ± 6.24 | 0.022 | 53.58 ± 7.68 | 0.043 | 58.16 ± 7.14 | 1    | 0.001 |
| Fovea                | 40.89 ± 5.82  | 36.55 ± 5.03 | <0.001 | 37.15 ± 5.55 | 0.022 | 40.88 ± 5.29 | 1    | <0.001|
| CC (%)               | 73.78 ± 3.39  | 71.18 ± 4.25 | 0.019 | 72.98 ± 4.80 | 0.875 | 73.35 ± 3.30 | 1    | 0.016 |
| Whole image          | 71.73 ± 4.19  | 68.62 ± 4.42 | 0.007 | 70.48 ± 4.68 | 0.922 | 71.81 ± 3.90 | 1    | 0.002 |
| Parafovea            | 71.63 ± 5.40  | 68.75 ± 4.92 | 0.048 | 71.23 ± 4.59 | 1    | 72.73 ± 4.63 | 0.836 | 0.002 |
| Fovea                | 0.263 ± 0.08  | 0.320 ± 0.08 | 0.011 | 0.265 ± 0.08 | 0.007 | 0.261 ± 0.07 | 1    | 0.002 |
| FAZ (mm²)            | 53.17 ± 4.14  | 46.04 ± 4.70 | <0.001 | 51.46 ± 4.11 | 0.602 | 52.18 ± 4.64 | 0.958 | <0.001|
| RPC (%)              | 54.74 ± 5.81  | 48.64 ± 4.09 | <0.001 | 52.57 ± 4.22 | 0.271 | 53.34 ± 4.17 | 0.947 | <0.001|

Data are expressed as mean ± SD, TDT: Transfusion Dependent Thalassemia, NTDT: Non-Transfusion Dependent Thalassemia, SCP: Superficial Capillary Plexus, DCP: Deep Capillary Plexus, FAZ: Foveal Avascular Zone, RPC: Radial Peripapillary Capillary, p: TDT vs. control group, p *: NTDT vs. control group, p †: β-thalassemia minor vs. control group, One-way analysis of variance (ANOVA) followed by Bonferroni post hoc analysis, Statistical significance p value < 0.05.
Figure 1. Top Row—Right eye of a 44 years-old male healthy subject shows normal thickness in Ganglion Cell Complex (GCC) (A) and in Retinal Nerve Fiber Layer (RNFL) (B) at structural spectral domain-optical coherence tomography (SD-OCT). Second Row—Left eye of a 43 years-old female patient with Transfusion Dependent Thalassemia shows focal reduction in GCC and RNFL thicknesses at SD-OCT (A1, B1). Third Row—Left eye of a 45 years-old female patient with Non-Transfusion Dependent Thalassemia shows absence of changes in GCC (A2) and RNFL (B2). Bottom Row—Left eye of a 44 years-old male patient with β-thalassemia minor shows absence of changes in GCC (A3) and RNFL (B3).
Significant negative correlation was shown between hemoglobin and foveal avascular zone \( (r = -0.437, p = 0.044) \) and between ferritin levels and RNFL average \( (r = -0.553, p = 0.011) \), CC whole \( (r = -0.431, p = 0.038) \), choriocapillaris parafovea \( (r = -0.459, p = 0.041) \) in \( \beta \)-thalassemia major group. No significant correlation was found in \( \beta \)-thalassemia intermediate and minor \( (p > 0.05) \).

4. Discussion

To our knowledge, this is the first cross-sectional study to analyze the retinal structural and vascular changes in macular and papillary regions in patients affected by \( \beta \)-thalassemia in different clinical phenotypes.

In TDT patients, the evaluation of structural SD-OCT parameters revealed a significant reduction in ganglion cell complex and retinal nerve fiber layer respect to controls and other study groups.

These findings could be explained by an iron overload due to transfusion therapy in order to counteract the chronic anemia [24]. Indeed, the free iron is involved in the genesis of the retinal nerve formation and in normal functioning of the neuronal cells [25,26].
but in these disorders, its high levels could cause free radicals production, due to the 
hemolysis, the iron chelation therapy and the decreased hepcidin levels that increase iron 
absorption [16,27–29].

According to previous studies, we hypothesized that in TDT patients, the tissue iron 
deposition could promote the neuronal cells death determining a thinning in ganglion 
cell complex and retinal nerve fiber layer, confirmed by the close correlation between the 
increased ferritin levels and the reduced thickness of the retinal nerve fiber layer [28,30,31].

Moreover, in our study, the patients with NTDT and β-thalassemia minor did not 
reveal changes in structural SD-OCT parameters, probably due to mild anemia and levels 
of ferritin within the normal that did not determine any neurodegenerative process, as 
shown also by Acer et al. [32].

The analysis of the retinal and choriocapillaris vessels by means OCTA allowed us to 
disclose the involvement of the microvascular networks in these disorders.

The patients with TDT showed a significant reduction in VD of the superficial capillary 
plexus and radial peripapillary capillary plexus with respect to other groups.

We hypothesized that both iron overload and the increased plasmatic free iron due 
to hemolysis, frequent blood transfusions could have determined an elevated oxidative 
status contributing to the retinal vascular damage in macula and papillary regions.

Moreover, the iron overload may play a key role also in the pathogenesis of endothelial 
dysfunction, due to the release of proinflammatory cytokines and adhesion molecules in 
these patients [33].

This impaired vascular perfusion may have determined a damage of the axoplasmic 
flow of the optic nerve, resulting in a significant retinal structural loss. Indeed, in the 
ganglion cell layer and the peripapillary retinal nerve fiber layer, the superficial capillary 
plexus and radial peripapillary capillary plexus that are responsible for their metabolic 
demand are localized, respectively [34].

In our results, the deep capillary plexus in TDT patients turned to be vulnerable 
to oxidative insult probably due to its reduced vascular caliber, smaller than superficial 
capillary plexus [34]. In this group, the foveal avascular zone area was involved by tissue 
hypoxia, showing a significant increase with respect to other β-thalassemia groups.

This area is extremely vulnerable to hypoperfusion damages that cause the drop out of 
the terminal interconnected capillaries at the margin of the fovea, coming from superficial 
and deep retinal vascular networks.

Therefore, the foveal avascular zone reflects the impairment of the retinal vessel 
density and it represents a sensible biomarker to ischemic insults [35]. This was confirmed 
by our results that showed the significant correlation between the reduced hemoglobin 
levels and the increased enlargement of foveal avascular zone area in TDT group.

The study conducted by Kazancı reported that in TDT, the foveal acircular index 
significantly correlated with hemoglobin levels, demonstrating the role of foveal avascular 
zone as sensible vascular biomarker in this disease [36]. Additionally, Georgalas et al. 
showed statistically significant differences in convexity, circularity and contour tempera-
ture of foveal avascular zone in TDT patients, with respect to controls, highlighting the 
relationship between the impairment of these parameters and the increased urine iron 
excretion [37].

In our results, the high serum ferritin levels due to hemolysis and the chronic blood 
transfusion significantly correlated with the choriocapillary hypoperfusion that is involved 
in the metabolic demand of the outer retinal layers and that could contribute to RPE 
damages [38,39] in TDT patients, as demonstrated by previous reports [40–43].

In this study, the patients with NTDT and β-thalassemia minor did not show changes 
in ganglion cell complex and retinal nerve fiber layer parameters, probably due to serum 
iron levels being normal.

In these groups, the retinal and the choriocapillaris microvascularization did not 
present significant impairment, while in NTDT, the deep capillary plexus turned to be 
reduced due to its reduced caliber vascular. These results could be due to the absence
of a severe hypoxia and an elevated oxidative status in β-thalassemia minor and NTDT. Otherwise, the mild anemia that characterizes these disorders could have determined a vascular compensation mechanism, resulting in a recovery of the vessel density.

This supposition was confirmed by the study conducted by Acer et al., who showed that β-thalassemia minor was a wider retinal arterial and venular caliber as a vascular response to mild hypoxia [32].

5. Conclusions

In conclusion, OCTA improved our knowledge of the pathophysiology of vascular perfusion in patients with β-thalassemia and could be a new vascular biomarker of this disease.

Further longitudinal studies with a wider study group and a longer follow up are needed to better explain the relationship between the retinal and choriocapillaris vascularization, structural retinal layers and the hematological parameters in different clinical phenotypes of β-thalassemia. Moreover, correlation studies between OCTA findings and the multisystem involvement in β-thalassemia patients could represent the objective of a future multidisciplinary work.

Author Contributions: Conceptualization, M.G.; G.C.; methodology, G.C.; D.M.; A.F.; formal analysis, P.R.; S.C.; F.A.; M.R.S.; investigation, D.M.; A.F.; M.G.; data curation, G.M.; F.A.; M.R.S.; P.R.; S.C.; A.S.; writing—original draft preparation, D.M.; G.C.; writing—review and editing, M.G.; G.C.; A.F.; supervision, M.G.; F.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Informed Consent Statement: Written informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to patients’ privacy.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Vichinsky, E.P. Changing patterns of thalassemia worldwide. *Ann. N. Y. Acad. Sci.* 2005, 1054, 18–24. [CrossRef]
2. Liaska, A.; Petrou, P.; Georgakopoulos, C.D.; Diamanti, R.; Papaconstantinou, D.; Kanakis, M.G.; Georgalas, I. β-Thalassemia and ocular implications: A systematic review. *BMC Ophthalmol.* 2016, 16, 102. [CrossRef] [PubMed]
3. Grosso, M.; Amendolara, M.; Recsighno, G.; Danise, P.; Todesico, N.; Izzo, P.; Amendola, G. Delayed decline of gamma-globin expression in infant age associated with the presence of Ggamma-158 (C–>T) polymorphism. *Int. J. Lab. Hematol.* 2008, 30, 191–195. [CrossRef] [PubMed]
4. Pepe, A.; Meloni, A.; Pistoia, L.; Cuccia, L.; Gamberini, M.R.; Lisi, R.; D’Ascola, D.G.; Rosso, R.; Allò, M.; Spasiano, A.; et al. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. *Br. J. Haematol.* 2018, 183, 783–795. [CrossRef] [PubMed]
5. Ricchi, P.; Ammirabile, M.; Spasiano, A.; Costantini, S.; Cinque, P.; Di Matola, T.; Pagano, L.; Prossomariti, L. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: A retrospective study. *Eur. J. Haematol.* 2010, 85, 36–42. [CrossRef]
6. Capolongo, G.; Zacchia, M.; Beneduci, A.; Costantini, S.; Cinque, P.; Spasiano, A.; De Luca, G.; Di Pietro, M.E.; Ricchi, P.; Trepiccione, F.; et al. Urinary Metabolic Profile of Patients with Transfusion-Dependent β-Thalassemia Major Undergoing Deferasirox Therapy. *Kidney Blood Press Res.* 2020, 45, 455–466. [CrossRef]
7. Rund, D.; Rachmilewitz, E. Beta-thalassemia. *N. Engl. J. Med.* 2005, 353, 1135–1146. [CrossRef]
8. Taneja, R.; Malik, P.; Sharma, M.; Agarwal, M.C. Multiple transfused thalassemia major: Ocular manifestations in a hospital-based population. *Indian J. Ophthalmol.* 2010, 58, 125–130. [CrossRef]
9. Wu, C.H.; Yang, C.P.; Lai, C.C.; Wu, W.C.; Chen, Y.H. Deferoxamine retinopathy:spectral domain-optical coherence tomography findings. *BMC Ophthalmol.* 2014, 2, 88–90. [CrossRef]
10. Rahi, A.H.; Hungerford, J.L.; Ahmed, A.I. Ocular toxicity of desferrioxamine: Light microscopic and ultrastructural findings. *Br. J. Ophthalmol.* 1986, 70, 373–381. [CrossRef]
11. Arden, G.B.; Wonke, B.; Kennedy, C.; Huehns, E.R. Ocular changes in patients undergoing long-term desferrioxamine treatment. *Br. J. Ophthalmol.* 1984, 68, 873–877. [CrossRef] [PubMed]
40. Bhoiwala, D.L.; Dunaief, J.L. Retinal abnormalities in β-thalassemia major. Surv. Ophthalmol. 2016, 6, 33–50. [CrossRef]

41. Van Bol, L.; Alami, A.; Benghiat, F.S.; Rasquin, F. Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: Report of two cases. Retin. Cases Brief Rep. 2014, 8, 97–102. [CrossRef] [PubMed]

42. Viola, F.; Barteselli, G.; Dell’Arti, L.; Vezzola, D.; Mapelli, C.; Villani, E.; Ratiglia, R. Multimodal imaging in deferoxamine retinopathy. Retina 2014, 34, 1428–1438. [CrossRef] [PubMed]

43. Viola, F.; Barteselli, G.; Dell’arti, L.; Vezzola, D.; Villani, E.; Mapelli, C.; Zanaboni, L.; Cappellini, M.D.; Ratiglia, R. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine. Ophthalmology 2012, 119, 1693–1700. [CrossRef] [PubMed]